The last few years have seen multiple financial and strategic accomplishments for Basilea. Cresemba continues to deliver strong in-market sales growth, and although it is maturing in the key markets of the US and Europe, it is still relatively early in its product life cycle in Japan and China, two significant markets. Nevertheless, the market is beginning to look beyond Cresemba, given its expected loss of exclusivity in the US from September 2027, and potential generic competition in Europe in H2 2028. With the novel antifungal fosmanogepix and antibiotic ceftibuten-ledaborbactam progressing through pivotal Phase 3 trials, US sales progress of Zevtera, and a strong early-stage pipeline, the long-term outlook for Basilea’s anti-infectives franchise looks highly promising.